General Principles ICH E8 (R1) for Clinical Studies

Protect clinical study participants by upholding the four pillars of subject protection: ethical conduct, confidentiality, safety information, and patient focus, aligned with ICH E6 (R1) principles.

Implement quality by design in clinical studies by balancing proactive design with retrospective learning, focusing on four elements, predefined objectives, and well-defined endpoints.

Define critical to quality factors in clinical studies per ICH E8 (R1), linking patient protection, reliable results, and risk-based decisions across protocol design, feasibility, safety, and reporting.

Plan drug development by adhering to scientific principles and good study design, coordinating with regulatory authorities, and incorporating post-approval studies, biomarkers, and regional health technology assessments.

Identify critical to quality factors for an investigational medicinal product by thorough characterization of the IMP, its formulation, and any administration device, within a development plan.

Bridge non-clinical studies to clinical trials with quality by design, ensuring sufficient non-clinical information supports initial human doses and exposure duration while identifying gaps that affect timing and scope.

Optimize clinical development planning using adaptive designs and real world evidence. Identify drug characteristics early, refine dose and endpoints, and focus on critical to quality factors across studies.

Discover how additional development extends the clinical studies lifecycle, covering new indications, populations, dosage regimens, routes of administration, or combinations, and rechecking critical to quality factors with prior study data.

Describe how a clinical development plan evolves from preclinical data through exploratory and confirmatory studies, addressing critical to quality factors: design, safety, feasibility, study conduct, reporting, and third-party engagement.

Define the study population with clear inclusion and exclusion criteria to align with objectives and study design stages: exploratory, confirmatory, and post-approval.

Identify and mitigate bias in clinical studies by evaluating blinding types, recognizing intercurrent events, and applying pre-specified rules and sensitivity analyses to ensure reliable results.

Engage early with statisticians to design and document the protocol and the statistical analysis plan, detailing the analysis of primary and secondary endpoints, interim analyses, missing data, and confounding factors.

Explore study data, including primary data from case report forms, labs, and patient-reported outcomes, and secondary data from external sources. Ensure data quality, protection, and use of international standards.

Establish safety monitoring to identify, monitor, and report concerns, protect participants, set withdrawal criteria in the protocol, and form a data monitoring committee to review data and preserve study integrity.

Technology evolves, enabling new study designs and broader data sources. Regulators safeguard subjects under the Declaration of Helsinki, keeping innovation aligned with ICH E8 (R1) and quality by design.